Radiation

Study Finds Significant Reduction in Esophageal Injury Rate When Using ensoETM™ During Cardiac Radiofrequency Ablation Procedures

Retrieved on: 
Monday, September 25, 2023
Science, Other Science, Biotechnology, Research, General Health, Health, Clinical Trials, Other Health, Radiation, FHRS, De novo, Atrial fibrillation, Esophageal disease, Esophagus, Multimedia, Temperature, Massage chair, AEF, NorthShore University HealthSystem, Cardiac electrophysiology, Hospital, AEF Monotrace, Journal, Patient, Fluoroscopy, Sutter Health, American College, Death, Liquor, Medical device, Doctor of Philosophy, MD

Esophageal injury can occur during ablation procedures for the treatment of atrial fibrillation, and an AEF is the most severe form of injury, resulting in death in most cases.

Key Points: 
  • Esophageal injury can occur during ablation procedures for the treatment of atrial fibrillation, and an AEF is the most severe form of injury, resulting in death in most cases.
  • View the full release here: https://www.businesswire.com/news/home/20230925491005/en/
    A peer-reviewed study in the Journal of the American College of Cardiology: Clinical Electrophysiology (JACC-EP) has found a significant reduction in the rate of atrioesophageal fistulas (AEFs) during cardiac ablation of the left atrium when using Attune Medical’s ensoETM proactive esophageal cooling device compared to luminal esophageal temperature monitoring.
  • The authors concluded that adoption of active esophageal cooling during RF ablation of the left atrium for the treatment of atrial fibrillation was associated with a significant reduction in AEF rate.
  • “This is the first study of the effectiveness of any technique to show a significant benefit in the reduction of AEFs.

Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting

Retrieved on: 
Monday, September 25, 2023
Astrocytoma, Poster, European Association for the Study of the Liver, Radiation, RT, Therapy, GBM, SAN, Neuro-Oncology (journal), Safety, Annual general meeting, Pharmaceutical industry

SAN DIEGO, Sept. 25, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, today announced the presentation of compelling patient case studies in a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting in Rotterdam.

Key Points: 
  • SAN DIEGO, Sept. 25, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, today announced the presentation of compelling patient case studies in a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting in Rotterdam.
  • In the first case, a 32-year-old woman with grade four GBM (MGMT-unmethylated) received conventional radiotherapy with concurrent chemotherapy with VAL-083 followed by adjuvant VAL-083 for a total of 13 cycles of VAL-083.
  • The patient was tumor-free and has survived more than four years as of the last follow-up in March 2023.
  • The patient was re-treated with VAL-083 and was stable as of the last follow-up in March 2023.

Vector Space Biosciences (SBIO) Is Now Available for Trading on LBank Exchange

Retrieved on: 
Sunday, September 24, 2023
Radiation, Cryptocurrency, Biotechnology, ORACLE, Ageing, ML, Research, Medicine, Protein, CubeSat, Lawrence Berkeley National Laboratory, LM, Artificial intelligence, Gene, Imperial College London, Road Town, Data science, Mobile phone, Medical imaging

Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023.

Key Points: 
  • Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023.
  • For all users of LBank Exchange, the SBIO/USDT trading pair is now officially available for trading.
  • Vector Space Biosciences specializes in harnessing language modeling, correlation matrix datasets, and real-time updates to uncover hidden relationships within scientific data, particularly in the realm of space biosciences.
  • Vector Space Biosciences collaborates with a diverse set of partners to facilitate new insights, hypotheses, interpretations, and discoveries in space biosciences for the benefit of humanity.

Fight Colorectal Cancer Hosts Congressional Black Caucus Panel to Tackle Disparities and Drive Progress

Retrieved on: 
Thursday, September 21, 2023
VCU Massey Cancer Center, Black and Brown!, Radiation, CRC, Education, ALC, Member of Congress, Detroit Black Community Food Security Network, Health equity, Congressional Black Caucus Foundation, Statistics, Large intestine, African Americans, Associate, Congress, Colorectal cancer, Patient, Cancer, A Call to Action: Women, Religion, Violence, and Power, Diagnosis, Mortality, Health, Conference, JAMA, Dairy, Birth control, Oncology, Black

Recognizing the urgency of this issue, Fight Colorectal Cancer (Fight CRC) , the nation's largest colorectal cancer (CRC) advocacy organization, is set to host their inaugural panel at The Congressional Black Caucus Foundation's Annual Legislative Conference (ALC) .

Key Points: 
  • Recognizing the urgency of this issue, Fight Colorectal Cancer (Fight CRC) , the nation's largest colorectal cancer (CRC) advocacy organization, is set to host their inaugural panel at The Congressional Black Caucus Foundation's Annual Legislative Conference (ALC) .
  • Scheduled for September 22, 9-10 am EST, this panel will convene experts, advocates, and policymakers to address the critical disparities in colorectal cancer outcomes among Black Americans.
  • Fight CRC's panel titled 'A Call to Action: Fighting Colorectal Cancer in the Black Community' is co-hosted by Members of Congress, including Representative Donald Payne Jr. (D-NJ) and Representative Nikema Williams (D-GA).
  • Colorectal cancer has a devastating impact on the Black community, with Black Americans being 20% more likely to receive a diagnosis of colorectal cancer compared to their white counterparts.

Association for the Advancement of Medical Instrumentation Awards Grants to Researchers at Michigan State, Emory University, BD Medical, PAXXUS, Inc.

Retrieved on: 
Tuesday, September 19, 2023
Emory University, Radiation, AAMI, Medium (website), Emory University Hospital, Research, Science, BD, Publicis Healthcare Communications Group, Patient safety, Comment, Michigan State University, Knowledge, Safety, Nursing, Medical device

The AAMI Foundation’s Kilmer Fund Committee awarded these grants to projects that seek to advance the science of microbiological quality and sterility assurance.

Key Points: 
  • The AAMI Foundation’s Kilmer Fund Committee awarded these grants to projects that seek to advance the science of microbiological quality and sterility assurance.
  • They include:
    $11,542 to Emory University and Emory University Hospital researchers to investigate autoclave steam effluent as a route to pathogen escape.
  • $10,000 to Michigan State University researchers to assess how healthcare workers respond to packing design features in sterility barrier packaging.
  • $13,767 to researchers at BD Medical’s Global Sterility Assurance to evaluate the effect of culture media selection and incubation conditions to recover radiation resistant microorganisms.

LDRA and Frontgrade Gaisler Collaborate to Enhance Software Development for Critical Systems

Retrieved on: 
Tuesday, September 19, 2023
Radiation, Computer, Research, LDRA, NASA, Risk, NPR, Safety, Software, Risk management

WIRRAL, UK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- WIRRAL, UK — Sept. 19, 2023— LDRA , a leading provider of software analysis and testing tools, and Frontgrade Gaisler , a world leader in embedded computer systems for harsh environments, today announced a new collaboration to advance software development for critical systems.

Key Points: 
  • WIRRAL, UK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- WIRRAL, UK — Sept. 19, 2023— LDRA , a leading provider of software analysis and testing tools, and Frontgrade Gaisler , a world leader in embedded computer systems for harsh environments, today announced a new collaboration to advance software development for critical systems.
  • The collaboration between LDRA and Frontgrade Gaisler offers customers in the space industry a range of valuable benefits.
  • "Through this collaboration, Frontgrade Gaisler and LDRA combine their strengths to offer a unified solution that addresses the critical needs of our customers," said Daniel Hellström, Software Section Head at Frontgrade Gaisler.
  • “Collaborating with Frontgrade Gaisler enables us to deliver an even more comprehensive solution for software analysis and testing in critical systems," said Ian Hennell, Operations Director, LDRA.

PreludeDx™ to Present New DCISionRT® Comparative Data in Oral Session at ASTRO 2023 Annual Meeting

Retrieved on: 
Tuesday, September 19, 2023
San Diego Convention Center, Cleveland Clinic, Impact, ASTRO, OH, Radiation, Woman, Radiation therapy, Ductal carcinoma, Therapy, IBR, MD, Medicine, Pregnancy Outcome Prediction study, DCIS, Patient, Society, American Society for Radiation Oncology, Medical imaging

LAGUNA HILLS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data using DCISionRT to identify limitations in current clinicopathologic factors alone to predict radiation benefit in women with ductal carcinoma in situ (DCIS).

Key Points: 
  • LAGUNA HILLS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data using DCISionRT to identify limitations in current clinicopathologic factors alone to predict radiation benefit in women with ductal carcinoma in situ (DCIS).
  • This comparison data was selected for a scientific session oral presentation at the 65th Annual American Society for Radiation Oncology (ASTRO) Meeting, to be held on October 1-4, 2023 at the San Diego Convention Center, San Diego, CA.
  • “We are pleased to have our new comparison data on DCISionRT selected for oral presentation at the prestigious ASTRO Annual Meeting,” said Dan Forche, President and CEO of PreludeDx.
  • “This new data is being presented by Dr. Frank A. Vicini, who will share how this data further validates the value of DCISionRT in guiding treatment decisions for DCIS patients.”
    Title: Number 100: Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-year Ipsilateral Breast Recurrence (IBR) Rates
    Presenter: Frank A. Vicini, MD, FASTRO, Radiation Oncologist at Michigan HealthCare Professionals, member of NRG Oncology, and first author of the study
    Title: Number 2439: Impact on Radiation Therapy Recommendation and Treatment Modality for Patients with Ductal Carcinoma in Situ Using the 7-Gene Biosignature: Analysis of the PREDICT Study
    Presenter: Chirag S. Shah, MD, Director of Breast Radiation Oncology, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands

Retrieved on: 
Monday, September 18, 2023
Radiation, Radionuclide, Neoplasm, Radiopharmaceutical, Protein, Patient, Invention, Isotope, Peptide, Pharmaceutical industry, Medical imaging, DARPin

INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and Athebio AG (“Athebio”), an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), today announced a collaboration and license agreement to develop and commercialize DARPin-targeted radioligands (“Radio-DARPins”).

Key Points: 
  • INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and Athebio AG (“Athebio”), an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), today announced a collaboration and license agreement to develop and commercialize DARPin-targeted radioligands (“Radio-DARPins”).
  • The collaboration gives POINT exclusive access to Athebio’s intellectual property and capabilities in DARPin development in the radioligand therapy field.
  • Together, the parties will collaborate in discovery, candidate selection and preclinical development of Athebody® DARPins for use as Radio-DARPin drug entities.
  • POINT will be solely responsible for the clinical development and commercialization of Radio-DARPins translated from the discovery collaboration.

USMI to Debut the Canady Robotic AI Surgical System at the First Global Surgical Oncology Summit Jerusalem, Israel January 2024

Retrieved on: 
Friday, September 22, 2023
Research, Technology, Medical Devices, Clinical Trials, Biotechnology, Health, Robotics, Science, Oncology, Artificial Intelligence, Radiation, GOOGLE, Freedom, Use, Controller, CAP, Female gendering of AI technologies, Endoscopy, Recognition, Intelligence, Multimedia, Immunotherapy, Doctor of Philosophy, Scientist, SIRI, Clinical trial, Motorized, MD, System, Intel Extreme Masters, Education minister, FACS, Artificial intelligence, Patient, Oncology nursing, FDA, Recurrence, Safety, SMART, Medical device, Laparoscopy

The Canady Robotic AI Surgical System is the world’s first AI robotic system that delivers cold atmospheric plasma (CAP) which is a three-dimensional non-contact bioelectric pulse electromagnetic field.

Key Points: 
  • The Canady Robotic AI Surgical System is the world’s first AI robotic system that delivers cold atmospheric plasma (CAP) which is a three-dimensional non-contact bioelectric pulse electromagnetic field.
  • The Canady Robotic AI Surgical System will be displayed at the First Global Surgical Oncology Summit in Jerusalem, Israel (January 30 to February 2, 2024).
  • View the full release here: https://www.businesswire.com/news/home/20230922283953/en/
    Canady Robotic AI Surgical System (Photo: Business Wire)
    The Canady Robotic AI Surgical System’s key components are a Motorized Positioning Arm, Speech Recognition Canady Electrosurgical Generator known as ORLI™, Controller for CAP Devices, Robotic Assisted End Effectors which can be used in Open, Laparoscopic, Thoracoscopic, Endoscopic and Mini-invasive surgical procedures.
  • Taisen Zhuang, PhD, Chief Technology Officer stated, “The Canady Robotic AI Surgical System sets a new precedent for Robotic Cancer Surgery by combining AI Technology and CAP.

Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics

Retrieved on: 
Wednesday, September 20, 2023
Other Health, Health, Technology, Artificial Intelligence, Cardiology, Exercise, DNA, Radiation, Epigenomics, Moyamoya disease, Personalized medicine, CT pulmonary angiogram, MD, Investment, Manuscript, Patient, Risk, Nested polymerase chain reaction, Artificial intelligence, Diagnosis, AI, SATRO-ECG, Death, CHD, PCR, Medical device, Research

Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that researchers from Cardio Diagnostics and Dr. Damon Broyles published a peer-reviewed article outlining scalable pathways that leverage precision epigenetics to revolutionize coronary heart disease (CHD) care globally, a leading cause of death worldwide in the journal Epigenomics.

Key Points: 
  • Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that researchers from Cardio Diagnostics and Dr. Damon Broyles published a peer-reviewed article outlining scalable pathways that leverage precision epigenetics to revolutionize coronary heart disease (CHD) care globally, a leading cause of death worldwide in the journal Epigenomics.
  • This review lays out an affordable, scalable framework to use artificial intelligence-guided epigenetic assessments for CHD risk assessment, diagnosis, and management.
  • The digital PCR-based approach requires only minimal infrastructure investments while providing unparalleled personalized biological insights into the drivers of each patient's CHD presentation.
  • "Our research shows a clear pathway for precision epigenetics to fill critical unmet needs in cardiac care on a national and global scale," said Dr. Robert Philibert, Chief Medical Officer and Co-Founder of Cardio Diagnostics.